Scholars Central

Conference abstractPublished 14 Dec 2018

PfSPZ vaccines: Developing a malaria vaccine to prevent infection, protect individuals and eliminate malaria in areas with intense transmission

Authors: Peter F Billingsley

Sanaria Inc. for the International PfSPZ Consortium, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cases and deaths caused by malaria worldwide increased in 2016. Prevalence of Plasmodium falciparum (Pf) by RDT was ~11% in 2-14-year olds on Bioko Island, Equatorial Guinea (EG) in 2017 compared to ~45% in 2004. Between 2004 and 2017, a national and international team supported by a technical advisory group instituted intense malaria control measures funded by one of the largest per capita investments in malaria control in the world. Consistent with prevalence reduction, malaria related mortality was reduced by ~85% and the EIR and basic case reproduction number (R0) by >90%. However, the prevalence as measured by RDT has remained stable recently (14% and 11% in 2012 and 2016), and qPCR studies in EG indicate prevalence is 3-fold higher. This situation is common in Africa. New tools are needed to move toward an R0 5,000 injections to >2,000 subjects of PfSPZ products and plans for Phase 3 and 4 trials and elimination campaigns will be presented.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Infectious Diseases & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Infectious Diseases & Therapy
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Peter F Billingsley”